<DOC>
	<DOCNO>NCT02698150</DOCNO>
	<brief_summary>HERMES pilot study aim explore impact remote monitoring patient severe functional mitral regurgitation undergo transcatheter mitral valve edge-to-edge repair Mitraclip system .</brief_summary>
	<brief_title>Remote Monitoring Patients With Functional Mitral Regurgitation Undergoing Mitraclip Transcatheter Repair</brief_title>
	<detailed_description>The scope HERMES study investigate whether information obtain remote monitoring patient severe functional mitral regurgitation undergone transcatheter mitral valve edge-to-edge repair Mitraclip system may potential guide treatment decision follow-up visit , improve quality life . Candidates Mitraclip procedure optimal medical therapy offer opportunity participate study bring home tablet series sensor wearables collect daily information blood pressure , oxygen saturation , weight variation , heart rate , symptom compliance therapy . These variable blind , store tablet download core institution follow-up visit . Clinicians encourage use data guide decision , personalize drug therapy follow-up schedule individual patient 's need . Patients run-in phase ( enrollment 30+-7 day ) use tablet &gt; 66 % day undergo Mitraclip procedure continue keep tablet 12 month ( active group ) . Patients run-in phase ( enrollment 30+-7 day ) use tablet &gt; 66 % day , continue study control group . Predefined clinical follow assessment collection study endpoint 1 month post Mitraclip , 6 month post Mitraclip 12 month post Mitraclip . Quality life , assess mean SF36v2 questionnaire , assess enrollment , pre Mitraclip , 1 month Mitraclip 12 month Mitraclip . A series secondary endpoint , include 6MWT assessment consumption resource also assess .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Symptomatic optimal medical therapy ( NYHA Class IIIIV ) Mitral regurgitation functional etiology Suitable Mitraclip candidate Life expectancy &gt; 12 month Mitral regurgitation primary etiology Refusal sign inform consent Dementia neurological disorder prevent proper use tablet Inability use tablet , sensor and/or wearable , even assistance family member Expected noncompliance followup visit Endstage chronic kidney disease dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mitral regurgitation</keyword>
	<keyword>Mitraclip</keyword>
	<keyword>Remote monitoring</keyword>
	<keyword>Wearables</keyword>
</DOC>